Skip to content
board-of-directors2

Board of Directors

With a combined expertise in science, business and biopharmaceuticals, our Board of Directors is well equipped to help Curemark carry out its vision of creating innovative treatments.

DR. JOAN FALLON

Founder and CEO

DR. JOAN FALLON

Founder and CEO

Dr. Fallon began her research on Autism and related disorders over 20 years ago and founded Curemark as a platform to develop product candidates to address her findings. Dr. Fallon has both clinical expertise and academic experience—the former from running a private practice specializing in pediatric development, and the latter as an Assistant Professor of Natural Sciences and Mathematics at Yeshiva University.

Dr. Fallon has played an integral role in two very successful (and unprecedented) medical ventures. She was an Oxford Health Plans board member and helped achieve underwriting authority from New York State, for alternative and complementary medicine where none had yet existed. She also helped implement a cost-effective, interdisciplinary health plan for Oxford that increased the level of quality care for all children enrolled there. Dr. Fallon has written numerous scholarly articles, lectured around the world on developmental problems in the pediatric population and served on the Board of Directors of the ICA and Kentuckiana Children’s Center. She serves as a Senior Advisor to the Henry Crown Fellows at The Aspen Institute, as well as a Distinguished Fellow at the Athena Center for Leadership Studies at Barnard College/Columbia University. She is also a member of the Board of Trustees of Franklin & Marshall College. Dr. Fallon holds a B.A. degree from Franklin and Marshall College, a DC degree from Palmer University, and has completed the coursework for the MSc in clinical investigation from Harvard University’s joint program with Massachusetts General Hospital.

JENNIFER R. FRIST

JENNIFER R. FRIST

Jennifer Frist is an investor in established and startup companies focusing on the healthcare, IT, hospitality, real estate and outdoor industries.

In addition to Curemark, her healthcare portfolio includes the Hospital Corporation of America (NYSE: HCA), a leading provider of healthcare services in the United States; RoundingWell, a privately held technology company that gives integrated care management to physicians and their patients; and Utilize Health, a privately-held technology company that matches patients with neurological disabilities to the therapies and facilities they need for the greatest potential for recovery.

Ms. Frist is actively involved in various Nashville non-profits. She has been a member of the Nashville Zoo Board of Directors for over 14 years, and is a past Chairman and current Chair of the Zoo’s $170 million capital campaign. Ms. Frist is also on the Board of Directors of the Nashville Public Education Foundation, Nashville Public Television and Tri-Star Centennial Medical Center. Ms. Frist holds a Bachelor of Science in Computer Science Engineering from Vanderbilt University.

ERIC R. HERMANN

President FH Asset Management LLC

ERIC R. HERMANN

President FH Asset Management LLC

Eric Hermann is the owner of FH International Financial Services, Inc. He has been active in emerging markets finance for over two decades, and has advised and managed funds investing in emerging markets debt instruments denominated in OECD currencies since 1992. In association with Carlson Investment Management, Mr. Hermann managed the First African Asset Fund Limited and the Africa High Yield Fund as well as the ML XVII Carlson (Cayman) CBO.

Mr. Hermann’s experience includes establishing the emerging markets trading and corporate finance units at Bear, Stearns & Co. Inc. and working as part of The Chase Manhattan Bank’s international banking group’s Africa and Middle East department. Mr. Hermann holds a Masters of Arts in Law and Diplomacy from the Fletcher School of Law and Diplomacy at Tufts University.

 

DR. JUSTIN STEBBING

DR. JUSTIN STEBBING

Justin Stebbing is a leading oncology expert. He has published over 500 peer-reviewed papers in journals including The New England Journal of Medicine, Blood, The Lancet and The Journal of Clinical Oncology, and is co-Editor-in-Chief of Oncogene. In addition, Dr. Stebbing has an extensive clinical practice and links this to a wide number of translational research studies.

Dr. Stebbing is a Fellow of the Royal College of Physicians and the Royal College of Pathologists and has been awarded the first NIHR translational research professorship in oncology from Great Britain’s National Institute for Health Research.

He has extensive biopharma investment experience, has previously served as an advisor to Atticus Capital and currently advises Lansdowne Partners. Dr. Stebbing earned his medical degree from Trinity College, Oxford, completed his residency at The Johns Hopkins Hospital in Baltimore, Maryland and received his PhD from Imperial College, London.